Qualigen Therapeutics, Inc. (NASDAQ:QLGN – Get Free Report) fell 7.3% on Wednesday. The company traded as low as $0.9135 and last traded at $0.9458. 269,386 shares traded hands during trading, a decline of 82% from the average session volume of 1,521,488 shares. The stock had previously closed at $1.02.
Qualigen Therapeutics Trading Down 7.3%
The company has a market capitalization of $1.60 million, a PE ratio of -0.13 and a beta of 0.24. The company has a fifty day simple moving average of $1.13 and a 200-day simple moving average of $1.22.
Qualigen Therapeutics Company Profile
Qualigen Therapeutics, Inc (NASDAQ: QLGN) is a clinical-stage biotechnology company focused on developing therapies for cancer and rare diseases. The company’s research programs are based primarily on small-molecule and nucleic-acid technologies intended to target biological mechanisms associated with tumor growth and disease progression.
Its oncology pipeline has included QN-302, an investigational small-molecule inhibitor of the transcription factor FOXM1 being studied for potential use in pancreatic cancer and other solid tumors.
See Also
- Five stocks we like better than Qualigen Therapeutics
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
